Business · Companies · 2 hrs ago
ResMed shares are down 10% ahead of quarterly results
ResMed shares are about 10% lower than a year ago, and the company is due to report first-quarter results on Friday.
Analysts forecast revenue of about US$1.39 billion, up roughly 4%, and adjusted earnings growth of about 5.5%.
The forecasts point to slower sales growth than last financial year, when revenue rose 10%.
ResMed sold its MatrixCare software business, and sales of its Astral ventilators are suspended after a safety issue, which could weigh on reported growth.
Investors will be watching demand for sleep apnoea treatments and whether the company can manage higher freight and component costs.
Sleep apnoea affects hundreds of millions of people worldwide, but ResMed estimates that fewer than 20% of people with the condition in the United States have been diagnosed or treated.
More diagnoses could create room for ResMed to grow, and the company is developing home testing options to help people access treatment sooner; the results on Friday will offer an update on its performance.
ResMed shares were trading around $35.50 on Wednesday, about 10% below their level a year earlier.
The company is due to report its first-quarter FY27 results on Friday.
Analysts forecast revenue of about US$1.39 billion, an increase of approximately 4%, and adjusted earnings growth of around 5.5%.
Sales of ResMed’s Astral ventilators have been suspended following a safety issue, and the company has sold its MatrixCare software business.
The article’s writer remains optimistic about ResMed’s long-term growth prospects and says they would buy shares before the results.
- Who
- ResMed Inc, whose shares trade on the ASX as RMD.
- What
- Its shares were around 10% lower than a year earlier ahead of its first-quarter FY27 results.
- When
- Wednesday, ahead of results due on Friday. The article was published on October 28, 2026.
- Where
- Not stated
- Why
- The article does not give a specific reason for the share decline. It notes the sale of MatrixCare and suspension of Astral ventilator sales, which could weigh on reported growth.
This story does not have two clearly opposing sides.
ResMed shares were trading around 10% higher than their level on Wednesday.
ResMed shares were trading around $35.50, about 10% lower than a year earlier.
ResMed is due to report its first-quarter FY27 results.
- Share price
- Around $35.50 on Wednesday
- Share performance
- Approximately 10% lower than a year earlier
- Expected revenue
- US$1.39 billion, up approximately 4%
- Expected adjusted earnings
- Around 5.5% growth
- Results
- First-quarter FY27 results due Friday
What people are saying
I would be happy buying ResMed shares before Friday's announcement.